Stocks of OPKO Health Inc. (NASDAQ:OPK) traded higher last session on Wall Street, down -3.30% to $2.05.
According to the data, OPKO Health Inc. (NASDAQ:OPK) has 6 analysts covering its stock. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $8.50 and a low of $2.00, we find $3.50. Given the previous closing price of $2.12, this indicates a potential upside of 65.09 percent. OPK stock price is now 18.05% away from the 50-day moving average and 35.07% away from the 200-day moving average. The market capitalization of the company currently stands at $1.64B.
A total of 0 analysts have issued a hold rating and 6 have given it a buy rating. Brokers who have rated the stock have averaged $4.32 as their price target over the next twelve months.
With the price target maintained at $2, Barrington Research recently Upgraded its rating from Mkt Perform to Outperform for OPKO Health Inc. (NASDAQ: OPK).
In other news, Nabel Gary J., Chief Innovation Officer bought 272,637 shares of the company’s stock on May 05. The stock was bought for $500,857 at an average price of $1.84. Upon completion of the transaction, the Chief Innovation Officer now directly owns 19,912,459 shares in the company, valued at $40.82 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 05, Chief Innovation Officer Nabel Gary J. bought 187,608 shares of the business’s stock. A total of $340,042 was incurred on buying the stock at an average price of $1.81. This leaves the insider owning 263,079 shares of the company worth $0.54 million. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OPK stock. A new stake in OPKO Health Inc. shares was purchased by ASSENAGON ASSET MANAGEMENT S.A. during the first quarter worth $2,505,000. INTRINSIC EDGE CAPITAL MANAGEMENT LLC invested $1,230,000 in shares of OPK during the first quarter. In the first quarter, FIRST TRUST ADVISORS LP acquired a new stake in OPKO Health Inc. valued at approximately $807,000. GROUP ONE TRADING, L.P. acquired a new stake in OPK for approximately $286,000. VERITION FUND MANAGEMENT LLC purchased a new stake in OPK valued at around $284,000 in the second quarter. In total, there are 282 active investors with 24.70% ownership of the company’s stock.
During the past 12 months, OPKO Health Inc. has had a low of $1.00 and a high of $2.77. As of last week, the company has a debt-to-equity ratio of 0.16, a current ratio of 1.80, and a quick ratio of 1.50. The fifty day moving average price for OPK is $1.7406 and a two-hundred day moving average price translates $1.5185 for the stock.
The latest earnings results from OPKO Health Inc. (NASDAQ: OPK) was released for Mar, 2023. According to the Diagnostics & Research Company, earnings per share came in at -$0.02, beating analysts’ expectations of -$0.08 by 0.06. This compares to -$0.08 EPS in the same period last year. The net profit margin was -31.90% and return on equity was -18.00% for OPK. The company reported revenue of $237.58 million for the quarter, compared to $329.22 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -27.84 percent. For the current quarter, analysts expect OPK to generate $201.97M in revenue.
OPKO Health Inc.(OPK) Company Profile
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company’s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women’s health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
